Crucially, posttreatment TBX21 expression predicts OS in both univariate and multivariable analyses across all patients with MM, irrespective of CMV status, suggesting a key role for this TF in mediating both CMV immunity and ICB response. This evidence concerns the gene TF and Miyoshi myopathy.